Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
  1. Home
  2. Search

Refine search

Refine search

Access:
Content type:
Publication date:
Apply   From and To filters
Subject: Show more
Journals Show more
Publishers: Show more
Societies Show more
Series: Show more
Collections: Show more

Actions for selected content:

Select all | Deselect all
  • View selected items
  • Export citations
  • Download PDF (zip)
  • Save to Kindle
  • Save to Dropbox
  • Save to Google Drive

Save Search

You can save your searches here and later view and run them again in "My saved searches".

Please provide a title, maximum of 40 characters.
Cancel
×

4 results

  • Chapter 7

  • R. John Aitken, University of Newcastle, New South Wales
  • Book:
    The Infertility Trap
    Published online:
    05 May 2022
    Print publication:
    05 May 2022, pp 238-269

  • Summary

    The Janus faces of IVFIn vitro fertilization therapy was originally pioneered by Edwards, Steptoe and Purdy in order to help women suffering from bilateral tubal occlusion. The subsequent rise of Assisted Reproductive Therapy (ART) as a default treatment for many different forms of human infertility has been successful to the point that it has now become a major industry that exists, not just to meet the needs of its desperate patients, but to satisfy the aspirations of its shareholders. The sheer scale of the demand for ART services in the future may create several issues that will have to be addressed, including the cost of providing equitable access to such therapy and meeting the long-term health needs of the children born as a result. When conducted at scale, the ART industry will also serve to retain poor fertility genes within the population. When combined with the lack of selection pressure on human fertility in advanced affluent societies, this feature will ensure that the incidence of infertility continues to rise, fuelling the need for more ART services in a self-perpetuating spiral. This may be a boon for business but will become a millstone for Governments trying to provide equitable access to healthcare services, including ART.

  • Chapter 25 - Analysis of embryo-derived factors as markers of developmental potential and viability

  • Edited by David K. Gardner, University of Melbourne, Botros R. M. B. Rizk, University of South Alabama, Tommaso Falcone
  • Book:
    Human Assisted Reproductive Technology
    Published online:
    16 May 2011
    Print publication:
    31 March 2011, pp 278-288

  • Summary

    This chapter examines the process of in vitro maturation (IVM), its efficacy and safety, and explores why it is not more routinely used to treat infertility and what is required to make it a more viable clinical option. The treatment of infertility is based on in vitro fertilization (IVF) as the technology of choice. IVM is an alternative approach for generating mature oocytes that eliminates or significantly reduces the need for hormonal stimulation of the ovary. The benefit of IVM is that the procedure removes the need to administer large multiple doses of follicle stimulating hormone (FSH) normally used in conventional IVF treatment to women. Current IVM conditions compromise subsequent embryo development rates following fertilization. It is concluded that IVM, despite the reduced efficiencies of implantation potential and increased early miscarriage, should be viewed as having no risk of an adverse outcome to mother and child compared with conventional IVF.

  • Chapter 37 - Tests for antisperm antibodies

  • Edited by Larry I. Lipshultz, Stuart S. Howards, University of Virginia, Craig S. Niederberger, University of Illinois, Chicago
  • Book:
    Infertility in the Male
    Published online:
    19 May 2010
    Print publication:
    24 September 2009, pp 603-612

  • Summary

    Many couples whose infertility treatment requires in-vitro fertilization (IVF) also need intracytoplasmic sperm injection (ICSI) as a part of the procedure. In many respects ICSI has revolutionized infertility treatment as a whole. Both research data and clinical experience have shown that providing a sperm sample during this crucial stage of IVF/ICSI treatment could increase performance anxiety for both fertile and infertile men. The successful use of assisted reproductive technologies over the past 25 years or more has brought with it procedures that allow couples who cannot conceive using their own gametes the alternative of achieving pregnancy through the use of donated oocytes, donated sperm, and even donated embryos. The psychological evaluation is also intended to rule out gross psychopathology and depression, potential substance abuse, as well as a history of current or past family violence or abuse. Marital stability is also assessed within the context of the consultation.

  • 72 - Infertility Treatment in Perimenopausal Women: Ethical Considerations

  • from PART IV - ETHICAL DILEMMAS IN FERTILITY AND ASSISTED REPRODUCTION
  • Edited by Botros R. M. B. Rizk, University of South Alabama, Juan A. Garcia-Velasco, Hassan N. Sallam, Antonis Makrigiannakis, University of Crete
  • Book:
    Infertility and Assisted Reproduction
    Published online:
    04 August 2010
    Print publication:
    15 September 2008, pp 723-727

  • Summary

    This chapter reviews the literature on the effects of age on fertility in the perimenopausal woman. The effect of age on female fertility is difficult to assess because of confounding variables such as coital frequency and other biological causes associated with infertility, the use of contraception and the social and economical constraints that limit family size. The most effective assisted reproductive technology (ART) treatment for perimenopausal women is oocyte donation. Infertility treatment in the perimenopausal woman raises many ethical questions. All fertility centers should establish guidelines based on the literature and their success rates to appropriately counsel patients about the likelihood of live birth based on age. These guidelines would also allow both the physician and the patient to justify treatment in those cases when the odds of success are low but are not nonexistent.